Anti-Amyloid Therapy Candidacy in APOE ε4 Heterozygotes with Prior Microhemorrhages | ApoE4 Insights

Clinical Content — For Licensed Healthcare Professionals Only
Clinical Pro Case-Based Clinical Reasoning

Anti-Amyloid Therapy Candidacy in an APOE ε4 Heterozygote with Prior Microhemorrhages

A nuanced shared decision-making framework for an 85-year-old biomarker-confirmed MCI patient at the intersection of multiple ARIA risk factors

Brian Paquette, DO, MPH · Neurology · Pain Medicine · Public Health · ApoE4 Insights

Index Case

An 85-year-old American man, retired allergist, APOE ε4/ε3 heterozygote. Biomarker-confirmed Alzheimer's disease: positive plasma pTau-217, reduced Aβ42/40 ratio, and positive amyloid PET. Formal neuropsychological testing confirms mild cognitive impairment (MCI). Prior brain MRI documented 4 cortical microhemorrhages. Repeat MRI performed — microhemorrhages are apparently absent. Patient is now considering anti-amyloid monoclonal antibody therapy (lecanemab or donanemab).

Clinical Question: Does apparent MRI resolution of microhemorrhages alter his ARIA risk classification and eligibility for anti-amyloid therapy?

01

The Microhemorrhage Pseudo-Resolution Problem

The apparent disappearance of cerebral microbleeds on a follow-up MRI is almost invariably a technical artifact rather than true biological resolution. Hemosiderin-laden macrophages — the pathological substrate of a prior microhemorrhage — represent a permanent histological finding. They do not spontaneously clear.

Detectability is highly dependent on: MRI field strength (3T vs. 1.5T), pulse sequence (susceptibility-weighted imaging [SWI] vs. T2*-GRE), slice thickness, and inter-scanner variability. A lesion visible on 3T SWI may not be reproduced on 1.5T GRE, creating a clinically dangerous illusion of resolution.

Evidence Base

Haller et al. (2018) in Radiology provide the reference standard review of cerebral microbleed imaging characteristics and inter-modality detection variability. Puy et al. (2021) in JNNP comprehensively address the gap between microbleed depiction and clinical interpretation, emphasizing that sequence mismatch accounts for the majority of apparent lesion disappearance on follow-up imaging.

⚠ Clinical Action Required Before Proceeding

Members Only

This review continues for members

The remainder of this article — the full clinical reasoning, evidence-strength tables, and complete reference list — is available to APOE4 Insights members.

  • Physician-authored, evidence-calibrated clinical reviews
  • Explicit about what the data do and do not support
  • No industry sponsorship, no supplement affiliates

$79 a year, with a 7-day free trial and a 30-day money-back guarantee. Founding members: $59/year with code FOUNDING.

Become a Member

Already a member? Log in

Similar Posts